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Abstract: Drug delivery systems have opened new avenues to improve the therapeutic effects of
already-efficient molecules. Particularly, Solid Lipid Nanoparticles (SLNs) have emerged as promising
nanocarriers in cancer therapy. SLNs offer remarkable advantages such as low toxicity, high
bioavailability of drugs, versatility of incorporation of hydrophilic and lipophilic drugs, and
feasibility of large-scale production. Their molecular structure is crucial to obtain high quality
SLN preparations and it is determined by the relationship between the composition and preparation
method. Additionally, SLNs allow overcoming several physiological barriers that hinder drug
delivery to tumors and are also able to escape multidrug resistance mechanisms, characteristic of
cancer cells. Focusing on cell delivery, SLNs can improve drug delivery to target cells by different
mechanisms, such as passive mechanisms that take advantage of the tumor microenvironment, active
mechanisms by surface modification of SLNs, and codelivery mechanisms. SLNs can incorporate
many different drugs and have proven to be effective in different types of tumors (i.e., breast, lung,
colon, liver, and brain), corroborating their potential. Finally, it has to be taken into account that
there are still some challenges to face in the application of SLNs in anticancer treatments but their
possibilities seem to be high.
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1. Introduction
1.1. Drug Delivery Systems
The development in the last fifty years of biochemistry, molecular biology, biophysics, and cell
biology, among other scientific disciplines, has led to significant advances in biomedicine based on
the molecular knowledge of many diseases. This has made possible the development of therapeutic
molecules effectively directed to the origin of the problem: the molecular and cellular processes that
lead to the development of diseases. This is particularly important in cancer research where continuous
progresses are made. Unfortunately, the development of new drugs is not enough to improve their
effects on therapy. Some drugs are poorly soluble in water and cannot be administered unless they
are encapsulated into drug carriers. In other occasions, drugs cannot permeate cell membranes and
as a consequence the concentration at the target site is insufficient. To overcome this, high doses of
drugs are required, causing high toxicity and many undesired side effects. Consequently, a targeted
drug delivery system could selectively carry sufficient drug concentrations into the targeted tissue
(or cell), improving its bioavailability and reducing the associated side effects due to high doses.
In this regard, nanotechnology has expanded the therapeutic options of a priori efficient molecules by
developing efficient Drug Delivery Systems (DDS). In fact, the application of nanotechnology in the
Nanomaterials 2019, 9, 474; doi:10.3390/nano9030474 www.mdpi.com/journal/nanomaterials
Nanomaterials 2019, 9, 474 2 of 20
administration and delivery of drugs has brought significant advances in medicine, promoting the
emergence of a new field: nanomedicine [1]. Diverse DDS have been developed by combining their
composition (organic, inorganic, or hybrid), size (small or large), shapes (sphere, rod, or cube), and
surface properties (surface charge, functional groups, PEGylation or other coating, and attachment of
targeting moieties) [2]. By doing so, different properties of therapeutic molecules, such as solubility,
pharmacokinetic profile, cellular uptake, biodistribution pattern, circulation time, and clearance
mechanisms, can be improved [1,2]. Thanks to the fast development of nanotechnology, there
is a vast variety of nanocarriers that offer a wide spectrum of options to treat each therapeutic
problem by a tailored approach. Among the most studied organic DDS it is worth mentioning
liposomes, dendrimers, polymeric nanoparticles or micelles, polymer–drug/protein conjugates,
and lipid nanoparticles. Additionally, some inorganic nanocarriers such as carbon nanotubes and
mesoporous silica nanoparticles have been developed [1–3].
1.2. Solid Lipid Nanoparticles
It is well known that lipid-based nanoparticles are less toxic and biocompatible compared to
inorganic or polymeric nanoparticles [4,5]. In particular, solid lipid nanoparticles (SLNs) have emerged
as an effective and promising alternative. They are colloidal particles of submicron size, with a
diameter between 50 and 1000 nm. They are made of a lipid matrix solid at physiological temperature,
surfactants and, in some occasions, by cosurfactants (Figure 1) [6].
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SLNs can be produced by different methods described exhaustively in the bibliography, such as
high shear homogenization and ultrasound, high-pressure homogenization, hot homogenization,
cold homogenization, solvent emulsification/evaporation, and microemulsion [6–9]. Among them,
the microemulsion method stands out for being an easy method that does not need very sophisticated
equipment or high-energy input and avoids the use of organic solvents. All these advantages
make the production of SLNs at large scale technically and economically feasible [10]. Nonetheless,
the correct composition is essential for the formation of microemulsions (thermodyna ically stable
an transparent mixtures), and therefore the optimization of the mixture is required.
1.3. Composition and Structure of Solid Lipid Nanoparticles
SLNs re versatile nanocarriers that have been applied to improve the therapeutic effect of
different molecules. However, the crystal structure of their lipid matrix is a crucial characteristic to
obtain high quality SLN formulations. This feature, the formation of the crystal solid state of the
lipids of the matrix, depends on the selection and relative proportion of the components, as well as on
the preparation method.
Since the composition of the nanoparticle has a great influence in the quality and characteristics of
SLNs, the appropriate composition should be chosen to each particular case [6].
Nanomaterials 2019, 9, 474 3 of 20
To do so, components of the lipid matrix must be carefully selected taking also into account the
nature of the drug to be incorporated since it has to be solubilized in the lipid matrix in order to have
good entrapment efficiency [11].
The most frequently used materials to form the lipid core are mono-, di-, and triglycerides,
fatty acids, fatty alcohols, and waxes, mainly because these lipids present good biocompatibility
and their melting point is above body temperature. The formation of a solid core is essential since
determines relevant characteristics of SLNs such as controlled drug release or particle stability [7].
Nonetheless, as described by the Thomson–Gibbs equation, the reduction of the diameter of a particle
produces a reduction of the melting point of the lipid. Therefore, lipids in nanoparticles do not always
behave as bulk lipids and during the production process of lipid nanoparticles supercooled melts
can appear (i.e., lipid structures that do not crystallize although being below its melting point) [12].
Consequently, the crystal structure of SLNs cannot be assumed when nanoparticle production process
is finished even selecting lipids that are solid at body temperature. Thus, analysis of the solid state of
the lipids with infrared spectroscopy or differential scanning calorimetry should be carried out after
SLN production in order to determine this characteristic [13]. Supercooled structures will tend to
crystallize within short period of time, which may lead to uncontrolled coalescence of lipid droplets
and formation of large crystals, leading to uncontrolled particle aggregation and enlargement.
On the contrary, in some special formulations, the melted lipids are stabilized and a liquid crystal
structure can be obtained [14–16]. These liquid crystals may flow like a liquid, but their molecules may
be oriented in a crystal-like manner. Besides, depending on the excipients and the applied method,
they can acquire different structures such as cubosomes, hexosomes, spongosomes, micellosomes, and
liposomes [17]. These lipid-based liquid crystals can also be applied as biocompatible and efficient
drug delivery systems, but they cannot be considered Solid Lipid Nanoparticles (as they do not present
a solid state) so they are not in the scope of this review.
Another SLN feature related to lipid solidification after nanoparticle production is that
depending on the nature of the lipid matrix and the production method, some nanoparticles can
crystalize in more than one crystal species [11]. Therefore, in a recrystallization process different
polymorphic forms can be generated driving to different internal structures. These polymorphic
forms are not long term stable and, after a period of time, lipid crystal structures can be transformed
producing more stable structures (Figure 2).
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Figure 2. Schematic representation of the energy landscape of different lipid structures and possible
polymorphic transformations. Black arrows represent crystallization process after nanoparticle
formation; different structures can be formed in the same process. Red arrows represent spontaneous
crystal structure transformation during nanoparticle storage.
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These possible postproduction polymorphic transitions are one of the main concerns about SLN
storage stability. Indeed, the polymorphic transitions add structural heterogeneity that impedes
the production and characterization of defined DDS, which is needed to fulfill pharmaceutical
standards. Additionally, crystal structure modifications can reduce the space to accommodate drug
molecules, thus, leading to drug expulsion and lowering drug entrapment efficiency. Furthermore,
these transformations can alter main nanoparticle characteristics such as size or shape [7].
Therefore, in some cases, crystallization process of the lipid matrix can be intentionally obstructed
in order to avoid drug expulsion related to polymorphic transitions. This can be achieved by adding
chemically very different liquid lipids or oils to the solid lipids. Hence, solid lipids cannot form perfect
crystals and they solidify producing different nanostructures. Nanoparticles formed by mixing solid
lipids and liquid lipids or oils are called nanostructured lipid carriers (NLCs) and are considered as
the second generation solid lipid nanoparticles because apart from avoiding drug expulsion they can
also improve initial loading capacity of the nanocarrier [18]. Depending on the nature of solid and
liquid lipid mixture, different types of nanostructures can be obtained: (i) the imperfect type; (ii) the
structureless type; and (iii) the multiple oil in solid fat in water (O/F/W) type (Figure 3) [18].
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Paying attention to other components of SLNs, the selection of proper surfactant molecules
can also be highly relevant be ause th y affect particl tability and have potenti l i plications i
the interactions of designed nanocarriers with ell . Surfactants have amphiphilic structure and
are oriented with their pol r he ds predominantly toward he queous phase while keeping their
hydrophobic groups aw y from water. The selection of surfactant m lecules mainly dep nds on the
chosen lipid, since they need t be physicochemically c mpatible [19]. Differ nt amphiphilic molecules
an be used as urfac ants: monoacylglycerides of long-chain fatty acids, phospholipids, some esters,
poloxamers, and polisorbates. Someti es, dditional molecules called cosurfactants are added in
order to improve particle stability. Mos used cosurfact nts are bile salts such as taurodeoxychol te,
or alcohols such as butanol or ethanol [6].
After choosing the right composition of SLNs for a determined purpose, interactions between
nanoparticle c mponents and their structural organization need to be evaluated. To do so, differ nt
biophysica techniques may be adapted to the study of SLNs. In fact, many authors have
applied techniques such s infrared spectroscopy, electron paramagnetic resonance (EPR), cryo-
and freeze-fra ture transmission electr n microsc py (Cryo-TEM), small-angle X-ray scatteri g
(SAXS), small-angle x-ray and neutron scattering (SANS), and x-ray powder pattern simulation
analysis (XPPSA) either alone or omb ed [20–23]. Depending n s lected excipients and pplied
characterization method two types of morphologies have been bserved in th se work : a platelet- ke
s pe (associated wi the stable β-polymorphic state) and a sph roidal or disk-like shape (relate to
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the α-polymorphic state). The surfactant molecules seem to form close-packed single molecular layers
at the interface of the nanoparticles and the dispersion medium [20].
1.4. Advantages and Disadvantages of SLNs
In general, one of the main concerns about the use nanoparticles composed of nonbiological
compounds (such as inorganic or polymeric nanoparticles) are the potential harmful effects that may
cause in our organism, as well as their instability after being administrated [3].
Due to their biocompatible nature, lipid nanoparticles are particularly interesting. In this regard,
liposomes represent one of the most used lipid DDS despite their low physical and chemical
stability [24].
An alternative to them can be offered by SLNs, formed by biocompatible and biodegradable lipids
that are solid at body temperature, making SLNs promising robust nanocarriers for controlled drug
delivery [25].
Apart from the abovementioned low toxicity and high stability, SLNs present other interesting
advantages, for instance, their high biocompatibility and biodegradability, and the remarkable capacity
to incorporate both hydrophilic and lipophilic compounds. In addition, they enable a controlled
release of the incorporated drug and they provide chemical protection and, therefore, high stability to
the incorporated compound [7]. Liquid crystal nanoparticles (LCNPs) also share these advantageous
characteristics and are also considered as very promising nanocarriers [17,26]. However, LCNPs have
not been widely applied yet, because of the high costs associated with the massive energy input
required in the manufacturing process [16].
In this regard, SLNs allow for simple and economical large-scale production [10,27], being some of
the most applied preparation methods microemulsion and high-pressure homogenization [6].
Another advantage of SLNs is the wide diversity of routes through which their administration is
effective: oral, parenteral, rectal, nasal, ocular, etc. [28]. Besides, they can be applied to treat a wide
range of diseases, including the use of SLNs in cancer treatment, in gene therapy by using cationic
SLNs, or even in the cosmetic field [6,29].
Nevertheless, as mentioned before, these nanoparticles also present some disadvantages related to
the recrystallization process, such as a low drug loading capacity and the possibility of drug expulsion
during SLN storage. All this, together with the high polydispersity shown by some SLN preparations,
may be limiting factors for the industrial production of this type of nanoparticles [28].
1.5. Cancer and Cancer Therapy
Cancer is a group of diseases that include the uncontrolled division of cells and resistance to cell
death, as well as the ability of these cells to invade other tissues [2]. It represents one of the leading
causes of death worldwide [30].
The most extended cancer treatment is the application of chemotherapy through conventional
drug administration, but it entails multiple problems, including low drug solubility, low specificity,
high toxicity, and low therapy index [2,31]. Another obstacle related to chemotherapy is cancer
cells’ resistance to drug treatments. This is known as multidrug resistance (MDR) and it refers to
the acquisition of resistance towards a broad spectrum of drugs [32]. Moreover, anticancer drugs
administration implies big discomfort to patients since they are essentially administered by injections
or intravenously and not by the oral route [33]. Nevertheless, despite all these limitations, nowadays
chemotherapy remains as the main cancer treatment [30].
DDS, specifically SLNs, can improve drug effect while overcoming resistance mechanisms.
The nanometric size of these systems, together with the possibility of ad hoc modifications, makes
them suitable to get through several biological barriers and to deliver drugs at the sites of interest with
minimal toxicity [6].
Aside from the already mentioned advantages, the use of SLNs in antitumor treatments could
also allow oral administration of drugs and improve the exposure time of cancer cells to medicines in
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comparison to the most frequent administration methods [33]. This would imply the use of simpler
and more convenient therapies for patients.
Considering the impact of cancer worldwide and the need of more efficient therapies, SLNs
are presented as particularly promising drug delivery systems for the improvement of cancer
chemotherapeutic treatments. Hence, the aims of this review are to gather relevant and current
information on the application of SLNs as drug delivery systems in antitumor treatments, to determine
the main barriers in cancer treatments and the importance of the mechanisms used by SLNs to improve
drug delivery, and to discuss the advances on the application of SLN and remaining challenges in
this field.
2. Obstacles for an Efficient Chemotherapy
2.1. Physiological Barriers
One of the first considerations to be made in chemotherapeutic treatments are the biological
barriers that drugs must overcome to reach their action sites. Focusing on oral administration, despite
being considered one of the most proper routes for the administration of medicines, it is not currently
an option used in chemotherapy due to the low bioavailability of drugs through this route [34].
After oral administration, the absorption process of molecules must be achieved.
The bioavailability of a compound is related to its absorption, which will depend on physicochemical
properties of the drug, emphasizing its solubility and permeability, and on physiological factors such
as pH conditions, patient’s dietary status, or regional differences in permeability [35].
For absorption to occur it is necessary that the drug gets dissolved in the gastrointestinal medium
and then the absorption process itself will take place in the small intestine. After absorption in
blood capillaries, the compounds are transferred through the liver before passing into systemic
blood circulation, there being exposed to metabolic enzymes. This hepatic metabolism represents
the main drawback in the absorption of drugs [29,35]. SLNs and other lipid formulations have been
reported to protect compounds against presystemic metabolism and to significantly improve intestinal
permeability and absorption, because of their lipophilic nature. In this way, SLNs could overcome this
barrier and improve drug administration, especially lipophilic drug administration [36,37].
Nevertheless, there may be other physiological obstacles in the administration of drugs,
for instance, when the target of the treatment in therapy against melanomas is the skin. In this
case, the stratum corneum acts as an important barrier, blocking penetration of many drugs. However,
lipid-based nanoparticles, in general, and SLNs, in particular, are able to enhance drug penetration
through the skin, especially those of smaller sizes [38]. There is more evidence that support the
use of SLNs for drug delivery through skin layers [39], thus it could be promising to apply this
methodology to create nanogel formulations for the treatment of cancer types such as the already
mentioned melanomas.
Of special concern in the administration of drugs to the central nervous system to treat brain
tumors is the blood–brain barrier (BBB) that represents a tremendous challenge. The BBB is essential
to maintain the microenvironment necessary for a suitable neuronal function. To this aim, the BBB
is formed by the microvascular endothelium of the brain whose functions, together with some cells
such as astrocytes, generate a barrier that separates circulating blood from brain nervous tissue [40].
The improvement of drug delivery to the brain through SLNs is based in the ability of these
nanoparticles to stabilize molecules and to increase their bioavailability and permeability. In treatments
targeting the central nervous system, the stability of a compound in plasma is essential to maintain
an acceptable concentration in order to achieve the desired pharmacological effect. SLNs improve
drug bioavailability, allowing the dose that reaches the brain to be higher in comparison to the
administration of the free drug. SLNs can also act as vehicles that interact with the barrier, therefore
favoring the penetration of drugs that initially could not cross it [41].
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Although SLNs enhance drug delivery through the BBB, other strategies based on these
nanoparticles could bypass this barrier. This could be achieved by drug administration via nasal
or intranasal route, exploiting a nose-to-brain drug delivery path. Nasal administration is a simple
method, which would not cause as much disturbs on patients as, for instance, the parenteral route.
The optimum nose-to-brain transport occurs through the olfactory epithelium, reaching the olfactory
bulb and then the central nervous system [42], and there is evidence reporting that SLNs properly
carry out this transport [43].
Finally, there are also barriers against the systemic use of SLNs themselves. For instance,
the reticuloendothelial system represents a significant limitation for nanocarriers, since it implies
their elimination from blood circulation. The mechanism consists of coating the nanoparticles by
plasma components such as albumin or immunoglobulin G, leading to their fast elimination by
phagocytic cells. Hence, this may seem to indicate that the effectiveness of nanoparticles will be
significantly reduced by the action of phagocytic cells. However, SLNs in the range of 120 to 200 nm
and coated by a hydrophilic surface are not rapidly phagocytize by reticuloendothelial system and
therefore they can perform their function more accurately [41].
2.2. Multidrug Resistance (MDR)
Together with the heterogeneity of tumors, one of the main challenges limiting the effectiveness of
antitumor chemotherapy is multidrug resistance (MDR), which can be intrinsic or acquired by exposure
to some compounds [44]. This capacity includes resistance to a numerous compounds with different
action mechanisms and chemical structure. MDR mechanisms can be classified into cellular and
noncellular, related to biochemical alterations in cancer cells and with tumor microenvironment,
respectively [45].
Cellular MDR are divided into several mechanisms (Figure 4). Nevertheless, the best characterized
and with the greatest contribution to MDR development is the efflux caused by the overexpression of
some membrane transporters as a consequence of exposure to cytotoxic drugs [46,47].
Figure 4. MDR mechanisms in cancer cells. Multidrug resistance can be associated to different
biochemical processes: (1) active efflux of compounds, (2) loss of surface receptors or alterations in the
cell membrane, (3) drug compartmentalization, (4) alteration of drug targets, (5) changes in the cell
cycle, (6) elevated drug metabolism, (7) activation of DNA damage repair systems, and (8) inhibition of
apoptosis. Adapted from [46].
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The alteration of the efflux transport in MDR is usually a consequence of a high expression of
ATP-binding cassette (ABC) transporters. This type of transporters reduces the intracellular
concentration of drugs and metabolites using energy obtained from ATP hydrolysis, and its main
function is the protection of cells against xenobiotics and toxic compounds [47]. Specifically,
P-glycoprotein or ABCB1 has an especially important role as an exporter in cancer cells due to
its location and its wide spectrum of substrates. In fact, ~90% of the drugs used in oncology are
substrates of this transporter [46,48].
On the other hand, focusing on noncellular MDR systems, the pathological conditions of cancer
shape the characteristic microenvironment of the tumor. Tumors are structures with a hypoxic nucleus
surrounded by proliferating cells. Their microenvironment aids in the proliferation, differentiation,
and growth of tumor cells, and it contributes notably to the development of MDR, reducing the action
or access of compounds [44].
Many systems based on nanomedicine are able to take advantage of the microenvironment of
the tumor for a more specific delivery [2]. In particular, SLNs are capable of overcoming many of
these resistance mechanisms because of two relevant features: (i) SLNs allow the cotransport of drugs
with molecules that inhibit MDR mechanisms [44] and (ii) SLNs can specially avoid the efflux by
exporters such as P-glycoprotein, probably due to a modulation of drug incorporation routes [48].
Thus, approaches based on advantageous characteristics of SLNs for a selective and/or more efficient
drug delivery could be crucial for future anticancer treatments using drug delivery systems.
3. Drug Delivery of SLNs
A selective delivery of drugs to their sites of action allows an improvement in their effectiveness,
as well as the reduction of their side effects [32]. In this regard, it has been described that SLNs can
improve their delivery by different mechanisms.
3.1. Passive Delivery Mechanisms
Specific accumulation of drugs in tumors could be achieved by in situ antitumor injections in the
specific areas where the tumor develops. However, in addition to being a more complicated treatment,
it is not always possible due to the difficulty of identifying cancerous masses [32]. To overcome
this difficulty, some delivery systems, in particular SLNs, allow the targeting of tumor tissues by
taking advantage of the characteristics of the tumor microenvironment, due to the so-called enhanced
permeability and retention effect (EPR) (Figure 5) [2]. This effect is mainly based in the fast angiogenesis
carried out by solid tumors to maintain enough supplies of oxygen and nutrients [31].
Figure 5. Enhanced permeability and retention effect in tumor tissues. Under normal conditions (a)
extravasation of the nanoparticles does not occur, but in the tumor region (b), the discontinuity of
the vascular epithelium and the poor functionality of the lymphatic drainage allow the increase of
permeability and retention of SLNs in the microenvironment of the tumor. Adapted from [31].
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The angiogenesis process in tumor regions promotes the development of irregular blood vessels
with discontinuous epithelium. These discontinuities between epithelial cells, with a size of 100 to
800 nm, allow nanoparticles of certain sizes to move through the interstitial space, being that the base
of the increased permeability. In addition, tumor tissues are characterized by a dysfunctional lymphatic
system, which implies insufficient lymphatic drainage, leading to the accumulation of nanoparticles in
the tumor tissue. This is the basis of increased retention [31,49].
Besides, molecule distribution according to the EPR effect is variable and is determined by three
interrelated processes: the extravasation of nanoparticles from the blood vessels, the diffusion of
nanoparticles through the tumor tissue, and the interaction with intra- or extracellular targets in the
microenvironment of the tumor [49].
Although the EPR effect is presented as a beneficial mechanism to improve the selective delivery of
drugs, in recent years it has been shown that the clinical results have not reached the expected potential.
This effect presents a high heterogeneity and depends on many factors, such as the type and size of the
tumor. Tumors where the greatest accumulation of nanomedicines has been found in relation to the
EPR effect are the pancreatic, colon, breast, and stomach tumors [50]. Therefore, when exploiting this
phenomenon for a specific delivery with SLNs, it could be necessary to take into account the specific
characteristics of the tumor.
3.2. Active Delivery Mechanisms
Active delivery mechanisms are focused on the recognition of target molecules such as receptors
or transporters overexpressed on the surface of tumor cells. Since the rate of cell proliferation in tumor
tissues is high, the demand of nutrients is elevated. Taking into account that most of these nutrients
require selective surface transporters to enter the cells, the expression of transporters in tumor cells
is consequently increased. Hence, transporter abundance could offer some additional advantages
comparing to surface receptors as targets, such as a broader spectrum of substrates [51].
Therefore, the idea of these therapies consists of directing the supply of pharmacological agents
selectively to cancer cells by modifying the surface of nanoparticles, thereby minimizing damage to
normal cells and avoiding undesired effects [31]. Specifically, the surface modification of nanoparticles
allows them to present multiple copies of the ligand of interest, so the binding avidity to the transporter
will be high [49].
It is remarkable that despite allowing a greater drug administration and selectivity, it is important
that the surface modification does not radically change nanoparticles biodistribution profile.
Furthermore, for the ligand–target interaction it is necessary for the nanocarriers to be close to their
target and besides, systems with high circulation times are required [49].
There are different ligands that can be used to carry out active drug delivery mediated by
SLNs. One of them is hyaluronic acid, since in several types of tumors there can be appreciated an
overexpression of its receptors (CD44 and CD168). Thus, it has been confirmed that SLNs loaded with
paclitaxel and with their surface functionalized with hyaluronic and pluronic acid (an inhibitor of the
efflux transporter P-glycoprotein) show the ability to overcome drug resistance and reduce cell viability
in HeLa cervix and MCF-7 breast tumor lines. Moreover, these SLNs increase drug concentration and
efficacy in a very significant way in tumor tissues in mice, in relation to SLNs without hyaluronic acid
and to the free drug [52].
As a different approach, it has been tested the modification of SLNs loaded with the drug
docetaxel with more than one ligand to allow a directed delivery, synergistically combining the
previously mentioned hyaluronic acid and tetraiodothyroacetic acid. The latter compound is an
analogue of thyroid hormones that has a high affinity for the integrin αvβ3, a molecule overexpressed
in tumor endothelial cells. In this way, the modification with tetraiodothyroacetic acid would allow the
transport of drugs to the surface of the tumors, enhancing the active delivery capacity of the hyaluronic
acid. Moreover, this hypothetical betterment was studied in vitro, showing high incorporation and
reduced viability in B16F10 mouse melanoma cells (expressing αvβ3 and CD44). These SLNs were
Nanomaterials 2019, 9, 474 10 of 20
also tested in vivo, in mice with lung tumors originated in situ and with implanted melanoma tumors,
observing a remarkable inhibition of tumor growth [53].
Another example could be the addition of sugars such as galactose to the nanoparticles surface for
a more efficient cell uptake of anticancer agents due to lectin receptors. In this way, galactosylation of
SLNs has been verified as an approach that favors their incorporation and cytotoxicity, for example,
when used for the transport of doxorubicin against A549 human lung epithelial cancer cells. Besides,
these SLNs have also been shown to improve drug distribution in tumors in mice, induced using the
A549 cell line [54].
3.3. Codelivery Mechanisms
A possibility to overcome drug resistance in tumor cells is the addition of two different compounds
to nanoparticles: the antitumor drug and an agent responsible to act against MDR mechanisms.
Some of the main strategies include, for instance, small interfering RNA (siRNA) to silence gene
expression of ABC transporters, microRNAs (miRNAs) that allow post-transcriptional regulation of
genes or inhibitory compounds of these exporters [44,55].
For example, among those mentioned inhibitory compounds, pluronic polymers have been shown
to be effective in reducing resistance mechanisms, especially in the inhibition of efflux transporters
overexpressed in the membrane of cancer cells. In addition to compounds capable of reversing MDR
mechanisms, it could also be adequate the application of compounds that prevent their appearance
or delay it. It has been studied the efficiency of different preventive agents coadministered with
cytotoxic drugs, and the combination seems to increase the effectiveness of chemotherapy. Among
them, dexrazoxane is capable of suppressing the stimulation of P-glycoprotein expression that drugs
can induce, thus preventing the development of MDR [56].
From another perspective, cotransport also includes the combined delivery of different types of
drugs. This could imply an optimization in the treatments, being able to be administered at the same
time and allowing a synergic effect in the action against tumor cells. The effectiveness of a combined
SLN drug delivery of the anticancer drug paclitaxel and the heat shock protein 90 (Hsp90) inhibitor
called tanespimycin has been confirmed. It has been shown that the inhibition of Hsp90 can repress
the expression of receptors that favor the growth of gastric tumors. The study concluded that this
codelivery results in an enhanced antitumor effect, reducing cell viability in different human gastric
cell lines and the weight and size of gastric tumors in mice [57].
As an interesting approach, it is possible to combine active targeting by SLN functionalization
and codelivery using different drugs. This was carried out using SLN modified with
polyethyleneglycol-distearoyl-phosphatidylethanolamine and functionalizing them with the
trans-activating transcriptional activator or TAT, a peptide that could allow a better penetration of
the nanocarriers into cells. The drugs for the codelivery were paclitaxel and cisplatin, being the last
one conjugated to α-tocopherol succinate, a derivative of vitamin E. Functionalization and codelivery
showed a synergic effect by improving cellular uptake in vitro in HeLa cells and antitumor activity
in vivo, by reducing the volume of cervical tumors in mice [58].
4. Drugs for Antitumor Treatments
SLNs allow the incorporation of multiple drugs—both hydrophilic and lipophilic. Depending on
the nanoparticles composition and the method of preparation, the drug can be incorporated in three
ways (Figure 6): (i) it can be dispersed homogeneously in the lipid matrix, (ii) it can be incorporated
into the shell surrounding said matrix, or (iii) it can be distributed in the outer shell [2].
In antitumor chemotherapy, the drugs used can be divided into alkylating agents, antimetabolites,
natural products, or hormonal compounds [30]. In this section, it will be exemplified that SLNs can
incorporate all of these types.
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Amo g the alkylating agents temozolomide can be outlined. This compound has three nitrogen
atoms adjacent to a heterocyclic ring that give an important anticancer activity. Temozolomide has
proved to be more effective when administered by SLNs in the treatment of melanomas, providing a
notably greater cytotoxicity in JR8, A2058 human, and B16-F10 mouse melanoma cell lines, compared to
free temozolomide. Moreover, in vivo application of temozolomide-loaded SLNs in mice with
melanoma tu rs verified that the use of these nanocarriers reduced tu or size by 50%, while
the drug in solution showed no significant effects [59].
The prodrug capecitabine is an antimetabolite that can be transformed into fluorouracil and it
is used against different types of cancers (breast or colon ca cer), but it has many harmful effects,
such as cardiotoxicity or nausea inductio . Capecitabine can be effectively loaded into SLNs, and
this formulation was evaluated both in vitro and in vivo. Cytotoxicity assays were performed with
HT-29 human colon cancer cells, and capecitabine incorporated into SLNs showed greater cytotoxic
capacity that the free drug. Moreover, it is worth mentioning that the SLN delivery system led to
enhanced bioavailability of the drug and reduced tumor histopathological alterations in rats it
1,2-dimethylhydrazine induced colon c ncer [60].
Docetaxel is a lipophilic natural product with antimitotic activity and low solubility in
water, so formulations with SLNs coul improve its administr ti n. This was demo strated in
pharmacokinetic studies by measuring its plasma concentration in rats, and it was concluded that
SLNs allow a greater absorption and less elimination. In addition, these systems were able to improve
the induction of cytotoxicity in MCF-7 breast tumor cells in relation to the drug in its commercial form
(in micelles) and in its free for [61].
Dox rubicin is another natural agent of great relevance as an anticancer compound.
Its administration shows several associated disadvantages such as heart problems, in addition to the
development of resistance by cancer cells. It has been observed that the incorporation of doxorubicin
in SLNs is possible and in combination with α-tocopherol succinate (which also presents anticancer
activity), it shows high cytotoxicity and high uptake capacity in resistant MCF-7 human breast and
NCI ovarian cancer cells [62].
There are more natural products that are used in cancer therapy, such as the aforementioned
paclitaxel, which causes cellular apoptosis [30]; another example is curcumin, a natural compound
with anti-inflammatory and antioxidant properties that also interferes with transduction routes and
induces cell cycle arrest or apoptosis [56,63].
It has also been reported that hormonal compounds can be incorporated into SLNs.
For instance, SLNs loaded with the estrogen receptor targeting tamoxifen have been tested against
tamoxifen-resistant MCF-7 breast cancer cells. The cytotoxic activity of tamoxifen and tamoxifen-SLN
were similar in nonresistant cells, although the reduction of cell viability by tamoxifen-SLN appeared
at earlier times. On the other hand, the treatment with free tamoxifen did not show antitumor
capacity against drug-resistant cells, whereas SLNs with tamoxifen were much more efficient and
aggressive [64].
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5. Effective Use of SLNs in Different Types of Tumors
It has been documented that SLNs are useful in the treatment of a wide variety of tumors.
In this section, to illustrate the applications and potential of SLNs as carriers of antitumor drugs,
we will focus on several types of tumors with significant prevalence and representing high threats,
in order to illustrate the applications and/or potential of SLNs as carriers of antitumor drugs: breast,
lung, colon, hepatic, and brain tumors [65]. The examples presented in this section are summarized in
Table 1.
Table 1. Use of SLNs against different types of tumors. Summary of studies related to the use of SLNs
to improve the action of anticancer drugs or agents. Studies applying SLNs against breast, lung, colon,
and brain tumors are included.
Tumor Type SLN Composition Drug Incorporated Reference
Breast
DOTAP, monestearin and Poloxamer 188 miRN-200c, combinedwith paclitaxel-NLC [58]
Trimyristin, egg L-α-PC DSPE-methylPEG-2000 Paclitaxel [66]
Cholesterol and Poloxamer 188 Curcumin [63]
Gelucire, stearyl amine, phospholipid 90 NG,
Tween 80 and fucose coating Methotrexate [67]
Lung
Glycerol monostearate, egg-PC,
Poloxamer 188, Tween 80 Naringenin [68]
Glycetyl stearate, cholesterol, D-α-tocopherol PEG
1000 succinate, sodium taurocholate,
and F-PEG-HTCC
Paclitaxel [69]
Glycerol monostearate, Poloxamer 188, and transcutol Erlotinib [70]
Colon
Resveratrol, stearic acid, sodium taurocholate,
Tween 80 and butanol Omega-3 PUFA [71]
Tristearin, Lipoid S75, Tween 80, DSPE, and folic acid Oxaliplatin [72]
Liver
Cetyl palmitate and Tween 80 Sorafenib tosylate andSPIONs [73]
Myristyl myristate/cetyl esters/cetyl palmitate,
and Pluronic F68 Linalool [74]
Brain
Cetyl palmitate and polysorbate 80 Indirubin [75]
Behenic acid and PVA 9000 Methotrexate [76]
Cetyl palmitate, Tween 80, ApoE, DSPE-PEG-avidin,
and/or palmitate-avidin - [77]
Leukemia Soy lecithin, Tween 80 and Compritol 888 ATO AP9-cd [78]
Prostate Stearic acid, and Poloxamer 188 Retinoic acid [79]
Melanoma α-Tocopheryl linolenate, sodium taurocholate,Tween 20, and butanol α-Linolenic acid [80]
Abbreviations: DOTAP: 1,2-dioleoyl-3-trimethylammonium-propane; PC: phosphatidylcholine; DSPE:
1,2-distearoyl-sn-glycero-3-phosphoethanolamine; PEG: polyethilene(glicol); F-PEG-HTCC: folate-poly(ethylene
glycol)-N-[(2-hydroxy-3-trimethyl-ammonium) propyl] chitosan; PUFA: polyunsaturated fatty acids; PVA:
hydrolyzed polyvinyl alcohol 9000–10,000 Mw; SPIONs: superparamagnetic iron oxide nanoparticles.
5.1. Breast Tumor
Breast cancer is the most common type of cancer in women and its prevalence keeps increasing
over the years [65]. There are different examples that reflect the effective use of SLNs to treat
these tumors.
For instance, it has been possible to carry out a delivery of a specific miRNA-200c in cationic
SLNs to avoid the resistance of breast cancer cells, and this was used to increase response to the drug
paclitaxel administered by NLC. The levels of this miRNA are decreased in breast cancer stem cells,
and its delivery by SLNs could lead to a reduced expression of class III beta-tubulin, which would
imply an increased effectiveness of microtubule-targeting drugs (such as paclitaxel). In this study,
MCF-7 breast cancer cells were used to generate mammospheres, and SLNs were able to transfect
these cells more efficiently than Lipofectamine or the free miRNA-200c, without affecting cell viability
or the morphology of mammospheres. Finally, it was possible to conclude that the use of this therapy
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improved the drug half maximum inhibitory concentrations (IC50) value of paclitaxel-loaded NLC
against cancer cells, and that it could be an adequate strategy for miRNA delivery in the treatment of
breast tumors [55].
In other works, paclitaxel-loaded SLNs were used against drug-resistant breast cancer cells.
Paclitaxel-SLN activity against MCF-7 drug-resistant and drug sensitive cells was compared to the
use of other formulations, such as dimethyl sulfoxide solubilization and Cremophor EL vehicles
(commercial formulation). The evaluation of concentration-dependent cytotoxicity indicated that
SLNs with paclitaxel notably improved the IC50 concentration in drug-resistant cells. Besides, these
nanocarriers provided an enhanced cellular uptake in relation to the other formulations especially in
drug-resistant cells, proving that SLNs are effective in avoiding multidrug resistance mechanisms in
breast cancer cells [66].
There are other studies that have also corroborated the effectiveness of SLNs, such as their
application as curcumin carriers against the breast cancer cell line MDA-MB-231. The results of
this work showed a strong increase in the drug uptake capacity of the cells when curcumin was
administered into the SLNs. Also, curcumin-SLN promoted a higher decrease in cell viability and an
increase in apoptotic cells than curcumin diluted in dimethyl sulfoxide [63].
Additionally, the efficacy of SLNs against breast tumors in vivo has been analyzed as well, further
demonstrating the importance of this DDS against breast tumors. For these experiments, SLNs were
loaded with methotrexate and functionalized with fucose to achieve an active targeting of tumors. First,
methotrexate showed a significantly increased cytotoxic effect in MCF-7 cells when incorporated into
fucose-SLNs than when incorporated into SLNs or alone. Also, methotrexate-loaded SLNs, especially
those modified with fucose, showed a greater concentration of the drug in tumor tissues together
with an improved antitumor effect in rats with induced breast cancer. As results from methotrexate
fucose-SLN and SLNs were more favorable than those from free methotrexate, it can be concluded that
in this case SLNs improved the treatment against breast tumors [67].
5.2. Lung Tumor
Lung tumors are one of the main types of cancer and the first cause of death due to cancer in
the United States [65], thus, the achievement of an effective and specific treatment is challenging.
For instance, SLNs have been analyzed as delivery systems of the anticancer compound naringenin.
It has been observed that although this system did not reduce cell viability in A549 lung epithelial
cells (probably due to the use of naringenin, which has not been reported to be effective against
A549 cells), naringenin-SLN showed a good cellular uptake pattern. Regarding biodistribution
studies in rats, the administration of naringenin with SLNs by intratracheal instillation ameliorated
the pharmacokinetic parameters of the drug, including mean residence time or maximum plasma
concentration [68].
Lung tumors have special interest because they can be treated using SLNs administered directly
into lungs by inhalation. However, this type of therapy is associated to certain limitations, such as short
residence times and little tolerance as a consequence of an uncontrolled drug release. In this regard,
paclitaxel loaded into SLNs has been used to revert some of these limitations, being those prepared
SLNs coated with a polymer formed by folate-poly(ethylene glycol) and chitosan. These studies
demonstrated that SLNs reduced the IC50 value in vitro against M109HiFR lung cancer cells. It was
also determined that SLNs were able to increase the drug concentration in vivo in lungs of healthy
and sick mice, when administered by inhalation [69].
Other researchers have reported that the incorporation of the poorly-soluble compound erlotinib
into SLNs could be useful against A549 cells and for inhalation administration. In vitro experiments
showed that the cytotoxic effect of the free drug was lower than the effect of the drug encapsulated in
SLNs. Furthermore, SLNs loaded with erlotinib presented an adequate aerosol dispersion performance,
indicating that this system could be suitable for pulmonary delivery [70].
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5.3. Colon Tumor
Colon cancer has a remarkable incidence in society and it is the third cause of death related to
cancer in the United States [65]. Therefore, finding strategies to act against this condition is essential.
Some works have demonstrated that SLNs could be a powerful method to treat colon tumors.
As an example, SLNs have been used to deliver omega-3 polyunsaturated fatty acids (α-linolenic
acid or docosahexaenoic acid) against HT-29 and GCT116 adenocarcinoma cells. In this experiments,
the SLNs proved to actively inhibit cell growth in a dose-dependent manner and more drastically than
the free fatty acids. More specifically, the incorporation of the fatty acid in SLNs slightly incremented
apoptosis activation and it strongly reduced cell proliferation in HT-29 cells [71].
Other studies have developed SLNs functionalized with folic acid for the delivery of oxaliplatin,
as folate receptors are overexpressed in colorectal carcinomas. After testing the antigrowth potential of
this formulation against HT-29 human colon cancer cells, oxaliplatin incorporated in SLNs with folic
acid showed the greatest anticancer capacity, comparing to nonfunctionalized SLNs and the free
drug [72].
5.4. Hepatic Tumor
Hepatic tumors represent also a considerable portion of deaths related to cancer and new
therapeutic approaches are needed [65]. Superparamagnetic iron oxide nanoparticles (SPIONs) can be
incorporated into SLNs to control delivery using an external magnetic field. Taking this into account,
SLNs were loaded with the drug sorafenib and SPIONs were added to HepG2 human hepatocarcinoma
cells. This drug delivery strategy showed a significant cytotoxic effect, but still not as strong as the
free drug. Despite this, the cellular uptake provided by SLNs and magnetic targeting experiments
evidenced that these nanoparticles may ameliorate hepatocarcinoma treatment [73].
In another work, SLNs with different lipid compositions were generated and the compound
linalool was added to those formulations. The antitumor capacity of these agents was verified not only
in a HepG2 human hepatocarcinoma cell line, but also in A549 lung adenocarcinoma cells. Focusing on
HepG2 cells, SLNs with linalool presented strong antiproliferative activity, which was dose- and
time-dependent [74].
5.5. Brain Tumor
Brain cancer represents a strong impact on the life of diagnosed patients and it supposes a serious
problem for health systems [40]. There are studies where SLNs have proven their capacity to improve
the treatment of this disease. One of those studies focused on the use of SLNs to deliver the drug
indirubin against a human U87MG glioblastoma-astrocytoma cell line. SLNs increased the cytotoxic
effect of the drug (especially in acidic conditions), demonstrating that these nanoparticles have the
potential to be applied against brain cancer cells [75].
As previously mentioned, it is complicated to treat brain tumors because the blood–brain barrier
represents a significant obstacle. To enhance drug delivery in these therapies, the surface of SLNs
can be modified with molecules that target receptors highly expressed in the blood–brain barrier.
For instance, SLNs can be coated with apolipoprotein E (ApoE), a molecule specifically recognized by
the receptors of low- or very low-density lipoproteins (LDL or VLDL). These receptors are expressed in
cells of the blood–brain barrier, and targeting them with ApoE would allow an active cellular uptake of
ApoE-SLN. Thus, this approach could increase the accumulation of nanoparticles in the brain [76,77].
SLNs that combine this ApoE surface modification together with the incorporation of the drug
methotrexate (as its lipophilic ester didoceylmethotrexate) have proven a reduction capacity of
glioblastoma tumors from F98/Fisher rat models. Besides, they exhibited a reduced elimination of
the drug from plasma and brain compared to the administration of the compound in free form [76].
It has also been verified that ApoE-modified SLNs enhanced cellular incorporation and transcytosis
through the blood–brain barrier. When SLNs were coated with ApoE using DSPE-PEG-avidin or
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palmitate-avidin as linkers, they were able to increase cellular uptake in a hCMEC/D3 cell monolayer
simulating the characteristics of the BBB [77].
5.6. Other Tumors
We have focused on the already-mentioned type of tumors due to their impact and prevalence,
but SLNs are efficient against other type of cancers. One of these types is leukemia in which it
has been evaluated the introduction of the lignin AP9-cd into SLNs to assess its anticancer activity.
SLNs with AP9-cd presented enhanced cytotoxic effects comparing to AP9-cd alone against human
leukemia Molt-4 cells. Moreover, AP9-cd incorporated into SLNs showed stronger antitumor capacity
in experimental Ehrlich ascites tumor model [78].
Another example would be the action of SLNs against prostate cancer. SLNs have been loaded
with retinoic acid, which presents very low aqueous solubility and the anticancer effect of retinoic acid
in SLNs was evaluated in LNCaP prostate cancer cells. Although free retinoic acid produced a greater
reduction in cell viability, the effect of retinoic acid-SLN was also relevant, and furthermore, the use of
SLNs solves the poor solubility of the drug [79].
In addition, SLNs based on α-tocopheryl linolenate were obtained in order to generate a novel
lipophilic formulation with intrinsic antitumor activity. These SLNs were further loaded with the
omega-3 α-linoleic acid in order to compare the synergic effect of α-tocopheryl linolenate-based
SLNs and α-linoleic acid. In vitro studies with C32 human melanoma cells indicated that both SLN
preparations showed cytotoxic activity in relation to the free compounds (α-tocopherol and α-linoleic
acid), proving once more the potential of SLNs [80].
6. Critical Discussion and Future Perspectives
In this work, we have reviewed state-of-the-art of SLN characteristics, advantages and
disadvantages, as well as the latest works related to application of SLNs to improve the actual
efficiency of anticancer drugs in different tumor types.
As detailed throughout this work, SLNs represent an innovative drug transport system that
allows for overcoming a great number of difficulties related to drug administration. Nevertheless,
it is also remarkable that these nanoparticles themselves have certain disadvantages or difficulties that
show the need to optimize some of their characteristics.
One of the main concerns related to SLN production is that polymorphic modification on the
crystal structure of SLNs can occur during storage time. This could lead to drug expulsion and
subsequent lowering of the drug loading capacity. Besides, polymorphic modification can induce
drastic changes in nanoparticle size and shape and these changes could destabilize the SLN suspension,
triggering particle aggregation. However, it has been described that SLNs formed by mixed lipids
allow the incorporation of larger amounts of drugs. Besides, this heterogeneity of the solid lipid matrix
also improves nanoparticles stability during storage, and thus, using mixtures of lipids could avoid
both problems [6]. To overcome these difficulties, new strategies have been explored. Specifically,
in NLCs formed by mixing solid lipid with liquid lipids, polymorphic modifications can be reduced
and drug loading capability can be increased. Thus, NLCs were produced in order to overcome
the difficulties related to SLNs. Nonetheless, instability problems such as particle aggregation or
unexpected gelation may occur in both SLNs and NLCs.
The abovementioned problems could be reduced in case we completely understood nanoparticle
formation process and structure because we could rationally modify the components and the processes
to form SLNs in order to obtain better characteristics. Unfortunately, due to reduced size and the
complexity of colloidal populations it is highly difficult to measure solidification process, particle
shape, and nanostructure or particle dynamics. Some advanced biophysical techniques such as cryo-
and freeze-fracture transmission electron microscopy, SAXS, and SANS are being applied to study SLN
structures and more research in this field is needed to obtain systematic understanding of the process of
SLN formation. Improving the application of these techniques would produce better knowledge and
Nanomaterials 2019, 9, 474 16 of 20
this would provide us the tools to perform a rational design of SLNs to achieve tailored improvement
in the efficiency of a given therapeutic treatment.
Moving onto tumor therapies, the capacity of SLNs to overcome a great part of MDR mechanisms
has been reported [48]. However, this may also indicate that these nanoparticles will not be effective in
any type of tumor. Instead, it will be dependent on the resistance characteristics developed by tumor
cells, since there will be resistance mechanisms that SLNs will not be able to revert.
Despite this, there are numerous studies that describe promising results when encapsulating
different drugs in SLNs and applying them as a strategy against cancer cells resistant to the drug.
These studies support the idea that these nanocarriers can effectively reverse the main resistance
mechanisms [47,48,64]. Nevertheless, it could be adequate to evaluate resistance factors of each tumor
to anticipate SLN efficacy in each specific treatment.
Another aspect that seems to generate controversy in the application of SLNs is the variability of
the EPR effect [50]. This effect depends on the characteristics of each tumor, thus, the formation of
a general strategy for cancer chemotherapies is not possible and therapies with active delivery
mechanisms remain more attractive. In this way, the use of active delivery systems could
also be reinforced by the ability of SLNs to improve their delivery in tumor regions where the
microenvironment of the tumor is favorable for that to happen [2].
All in all, there are many drugs that have been incorporated in SLNs with positive results [30,59–64],
as well as tumors in which their action has been verified [58,63,66–80]. These are the main supports for
the advance in research on the use of SLNs in tumor treatments.
Overall, SLNs seem to be a promising strategy in the fight against cancer diseases. Therefore, as
a future perspective, a line of research focused on the development of surface-modified SLNs could
have great interest for an active and specific delivery in different types of tumors, with different
resistance mechanisms associated. This could be very useful in order to find individualized and highly
effective therapies.
7. Conclusions
SLNs provide a biocompatible DDS that can be used to incorporate a wide variety of drugs and
to treat different types of tumors while overcoming resistance mechanisms in cancer cells. In addition,
SLNs facilitate the cellular uptake of the incorporated drugs by the modulation of passive, active,
and cotransport mechanisms and are able to overcome biological barriers. Nevertheless, as we have
mentioned in this work, better understanding of SLN formation, nanostructure, and drug loading
would lead us to the rational design of tailored SLNs for each cancer treatment.
Author Contributions: Conceptualization, L.B.-C. and L.A.; Writing-Original Draft Preparation, L.B.-C., I.A. and
L.A.; Funding Acquisition, I.A.
Funding: This work was supported by grant GIU (2018) GIU18/229.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Limeres, M.J.; Moretton, M.A.; Bernabeu, E.; Chiappetta, D.A.; Cuestas, M.L. Thinking small, doing big:
Current success and future trends in drug delivery systems for improving cancer therapy with special focus
on liver cancer. Mater. Sci. Eng. C Mater. Biol. Appl. 2019, 95, 328–341. [CrossRef] [PubMed]
2. Din, F.U.; Aman, W.; Ullah, I.; Qureshi, O.S.; Mustapha, O.; Shafique, S.; Zeb, A. Effective use of nanocarriers
as drug delivery systems for the treatment of selected tumors. Int. J. Nanomed. 2017, 12, 7291–7309. [CrossRef]
3. Prasad, P.V.; Shrivastav, T.G. Nanotechnological contribution to drug delivery system: A reappraisal.
J. Biomater. Nanobiotechnol. 2014, 5, 194–199. [CrossRef]
4. Kumar, N.; Kumar, R. Nanotechnology and Nanomaterials in the Treatment of Life-threatening Diseases; William
Andrew: Waltham, MA, USA, 2013.
Nanomaterials 2019, 9, 474 17 of 20
5. Muller, R.H.; Shegokar, R.; Keck, C.M. 20 years of lipid nanoparticles (SLN & NLC): Present state of
development & industrial applications. Curr. Drug Discov. Technol. 2011, 8, 207–227. [CrossRef] [PubMed]
6. Geszke-Moritz, M.; Moritz, M. Solid lipid nanoparticles as attractive drug vehicles: Composition, properties
and therapeutic strategies. Mater. Sci. Eng. C Mater. Biol. Appl. 2016, 68, 982–994. [CrossRef]
7. Mehnert, W.; Mäder, K. Solid lipid nanoparticles: Production, characterization and applications. Adv. Drug
Deliv. Rev. 2001, 47, 165–196. [CrossRef]
8. Wissing, S.A.; Kayser, O.; Müller, R.H. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Deliv.
Rev. 2004, 56, 1257–1272. [CrossRef] [PubMed]
9. Gordillo-Galeano, A.; Mora-Huertas, C.E. Solid lipid nanoparticles and nanostructured lipid carriers:
A review emphasizing on particle structure and drug release. Eur. J. Pharm. Biopharm. 2018, 133, 185–308.
[CrossRef]
10. Marengo, E.; Cavalli, R.; Caputo, O.; Rodriguez, L.; Gasco, M.R. Scale-up of the preparation process of solid
lipid nanospheres. Part I. Int. J. Pharm. 2000, 205, 3–13. [CrossRef]
11. Doktorovova, S.; Shegokar, R.; Souto, E.B. Chapter 30—Role of excipients in formulation development
and biocompatibility of lipid nanoparticles (SLNs/NLCs). In Nanostructures for Novel Therapy; Elsevier:
Amsterdam, The Netherlands, 2017; pp. 811–843.
12. Westesen, K.; Bunjes, H. Do nanoparticles prepared from lipids solid at room temperatura always possess a
solid lipid matrix? Int. J. Pharm. 1995, 115, 129–131. [CrossRef]
13. Arana, L.; Salado, C.; Vegas, S.; Aizpurua-Olaizola, O.; de la Arada, I.; Suarez, T.; Usobiaga, A.; Arrondo, J.L.;
Alonso, A.; Goñi, F.M.; et al. Solid lipid nanoparticles for delivery of Calendula officinalis extract. Colloids
Surf. B Biointerfaces 2015, 135, 18–26. [CrossRef]
14. Tongcher, O.; Sigel, R.; Landfester, K. Liquid crystal nanoparticles prepared as miniemulsions. Langmuir
2006, 22, 4504–4511. [CrossRef]
15. Murgia, S.; Falchi, A.M.; Mano, M.; Lampis, S.; Angius, R.; Carnerup, A.M.; Schmidt, J.; Diaz, G.; Giacca, M.;
Talmon, Y.; et al. Nanoparticles from lipid-based liquid crystals: Emulsifier influence on morphology and
cytotoxicity. J. Phys. Chem. B 2010, 114, 3518–3525. [CrossRef]
16. Lee, D.R.; Park, J.S.; Bae, I.H.; Lee, Y.; Kim, B.M. Liquid crystal nanoparticle formulation as an oral drug
delivery system for liver-specific distribution. Int. J. Nanomed. 2016, 11, 853–871. [CrossRef]
17. Angelova, A.; Garamus, V.M.; Angelov, B.; Tian, Z.; Li, Y.; Zou, A. Advances in structural design of
lipid-based nanoparticle carriers for delivery of macromolecular drugs, phytochemicals and anti-tumor
agents. Adv. Colloid Interface Sci. 2017, 249, 331–345. [CrossRef]
18. Müller, R.H.; Radtke, M.; Wissing, S.A. Nanostructured lipid matrices for improved microencapsulation of
drugs. Int. J. Pharm. 2002, 242, 121–128. [CrossRef]
19. Severino, P.; Andreani, T.; Marcedo, A.S.; Fangueiro, J.F.; Santana, M.H.; Silva, A.M.; Souto, E.B. Current
state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J. Drug Deliv. 2012,
2012, 750891. [CrossRef]
20. Schmiele, M.; Schindler, T.; Unruh, T.; Busch, S.; Morhenn, H.; Westermann, M.; Steiniger, F.; Radulescu, A.;
Lindner, P.; Schweins, R.; et al. Structural characterization of the phospholipid stabilizer layer at the
solid-liquid interface of dispersed triglyceride nanocrystals with small-angle x-ray neutron scattering.
Phys. Rev. E 2013, 87, 062316. [CrossRef]
21. Liu, D.; Chen, L.; Jiang, S.; Zhu, S.; Qian, Y.; Wang, F.; Li, R.; Xu, Q. Formulation and characterization of
hydrophilic drug diclofenac sodium-loaded solid lipid nanoparticles based on phospholipid complexes
technology. J. Liposome Res. 2014, 24, 17–26. [CrossRef]
22. Barbosa, R.M.; Casadel, B.R.; Duarte, E.L.; Severino, P.; Barbosa, L.R.S.; Duran, N.; de Paula, E. Electron
paramagnetic resonance and small-angle X-ray scattering characterization of solid lipid nanoparticles and
nanostructured lipid carriers for dibucaine encapsulation. Langmuir 2018, 34, 13296–13304. [CrossRef]
23. Yokaichiya, F.; Schmidt, C.; Storsberg, J.; Kumpugdee-Vollrath, M.; Ribeiro de Araujo, D.; Kent, B.;
Clemens, D.; Wingert, F.; Franco, M.K. Effects of doxorubicin on the structural and morphological
characterization of solid lipid nanoparticles (SLN) using small angle neutron scattering (SANS) and small
angle X-ray scattering (SAXS). Phys. B Condens. Matter 2018, 551, 191–196. [CrossRef]
24. Sharma, A.; Sharma, U.S. Liposomes in drug delivery: Progress and limitations. Int. J. Pharm. 1997, 154,
123–140. [CrossRef]
Nanomaterials 2019, 9, 474 18 of 20
25. Shah, R.; Eldridge, D.; Palombo, E.; Harding, I. Optimisation and stability assessment of solid lipid
nanoparticles using particle size and zeta potential. J. Phys. Sci. 2014, 25, 59–75.
26. Chen, Y.; Angelova, A.; Angelov, B.; Drechsler, M.; Garamus, V.M.; Willumeit-Römer, R.; Zou, A. Sterically
stabilized spongosomes for multidrug delivery of anticancer nanomedicines. J. Mater. Chem. B 2015, 3,
7734–7744. [CrossRef]
27. Dingler, A.; Gohla, S. Production of solid lipid nanoparticles (SLN): Scaling up feasibilities. J. Microencapsul.
2002, 19, 11–16. [CrossRef] [PubMed]
28. Ramteke, K.H.; Joshi, S.A.; Dhole, S.N. Solid lipid nanoparticle: A review. IOSR J. Pharm. 2012, 2, 34–44.
29. Nair, A.T.; Deshkar, S.S.; Boraste, S.S.; Sharma, R.M. Solid lipid nanoparticles a potential approach for
delivery of lipophilic drugs: A review. J. Pharm. Pharm. Sci. 2016, 5, 2238–2253. [CrossRef]
30. Chen, Z.; Zheng, Y.; Shi, Y.; Cui, Z. Overcoming tumor cell chemoresistance using nanoparticles: Lysosomes
are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles. Int. J. Nanomed. 2018, 13,
319–336. [CrossRef]
31. Sun, T.; Zhang, Y.S.; Pang, B.; Hyun, D.C.; Yang, M.; Xia, Y. Engineered nanoparticles for drug delivery in
cancer therapy. Angew. Chem. Int. Ed. Engl. 2014, 53, 12320–12364. [CrossRef]
32. Moon, J.H.; Moxley, J.W.; Zhang, P.; Cui, H. Nanoparticle approaches to combating drug resistance. Future
Med. Chem. 2015, 7, 1503–1510. [CrossRef]
33. Mei, L.; Zhang, Z.; Zhao, L.; Huang, L.; Yang, X.L.; Tang, J.; Feng, S.S. Pharmaceutical nanotechnology for
oral delivery of anticancer drugs. Adv. Drug Deliv. Rev. 2013, 65, 880–890. [CrossRef]
34. Lin, C.H.; Chen, C.H.; Lin, Z.C.; Fang, J.Y. Recent advances in oral delivery of drugs and bioactive natural
products using solid lipid nanoparticles as the carriers. J. Food Drug Anal. 2013, 25, 219–234. [CrossRef]
35. Shekhawat, P.; Pokharkar, V. Understanding peroral absorption: Regulatory aspects and contemporary
approaches to tackling solubility and permeability hurdles. Acta Pharm. Sin. B 2017, 7, 260–280. [CrossRef]
36. Zupancˇicˇ, O.; Bernkop-Schnürch, A. Lipophilic peptide character—What oral barriers fear the most. J. Control.
Release 2017, 255, 242–257. [CrossRef]
37. Masiiwa, W.L.; Gadaga, L.L. Intestinal permeability of artesunate-loaded solid lipid nanoparticles using the
everted gut method. J. Drug Deliv. 2018, 2018, 3021738. [CrossRef]
38. Mardhiah Adib, Z.; Ghanbarzadeh, S.; Kouhsoltani, M.; Yari Khosroshahi, A.; Hamishehkar, H. The effect of
particle size on the deposition of solid lipid nanoparticles in different skin layers: A histological study. Adv.
Pharm. Bull. 2016, 6, 31–36. [CrossRef]
39. Rostamkalaei, S.S.; Akbari, J.; Saeedi, M.; Morteza-Semmani, K.; Nokhodchi, A. Topical gel of metformin
solid lipid nanoparticles: A hopeful promise as a dermal delivery system. Colloids Surf. B Biointerfaces 2019,
175, 150–157. [CrossRef]
40. Mazur, J.; Roy, K.; Kanwar, J.R. Recent advances in nanomedicine and survivin targeting in brain cancers.
Nanomedicine 2018, 13, 105–137. [CrossRef]
41. Gastaldi, L.; Battaglia, L.; Peira, E.; Chirio, D.; Muntoni, E.; Solazzi, I.; Gallarate, M.; Dosio, F. Solid lipid
nanoparticles as vehicles of drugs to the brain: Current state of the art. Eur. J. Pharm. Biopharm. 2014, 87,
433–444. [CrossRef]
42. Costa, C.; Moreira, J.N.; Amaral, M.H.; Sousa Lobo, J.M.; Silva, A.C. Nose-to-brain delivery of lipid-based
nanosystems for epileptic seizures and anxiety crisis. J. Control. Release 2019, 295, 187–200. [CrossRef]
43. Fatouh, A.M.; Elshafeey, A.H.; Abderlbary, A. Intranasal agomelatine solid lipid nanoparticles to enhance
brain delivery: Formulation, optimization and in vivo pharmacokinetics. Drug Des. Dev. Ther. 2017, 11,
1815–1825. [CrossRef]
44. Kapse-Mistry, S.; Govender, T.; Srivastava, R.; Yergeri, M. Nanodrug delivery in reversing multidrug
resistance in cancer cells. Front. Pharmacol. 2014, 5, 1–22. [CrossRef]
45. Kartal-Yandim, M.; Adan-Gokbulut, A.; Baran, Y. Molecular mechanisms of drug resistance and its reversal
in cancer. Crit. Rev. Biotechnol. 2016, 36, 716–726. [CrossRef]
46. Alakhova, D.Y.; Kabanov, A.V. Pluronics and MDR reversal: An update. Mol. Pharm. 2014, 11, 2566–2578.
[CrossRef]
47. Bugde, P.; Biswas, R.; Merien, F.; Lu, J.; Liu, D.X.; Chen, M.; Zhou, S.; Li, Y. The therapeutic potential of
targeting ABC transporters to combat multi-drug resistance. Expert Opin. Ther. Targets 2017, 21, 511–530.
[CrossRef]
Nanomaterials 2019, 9, 474 19 of 20
48. Cavaco, M.C.; Pereira, C.; Kreutzer, B.; Gouveia, L.F.; Silva-Lima, B.; Brito, A.M.; Videira, M. Evading
P-glycoprotein mediated-efflux chemoresistance using solid lipid nanoparticles. Eur. J. Pharm. Biopharm.
2017, 110, 76–84. [CrossRef]
49. Bertrand, N.; Wu, J.; Xu, X.; Kamaly, N.; Farokhzad, O.C. Cancer nanotechnology: The impact of passive and
active targeting in the era of modern cancer biology. Adv. Drug Deliv. Rev. 2014, 66, 2–25. [CrossRef]
50. Natfji, A.A.; Ravishankar, D.; Osborn, H.M.I.; Greco, F. Parameters affecting the enhanced permeability and
retention effect: The need for patient selection. J. Pharm. Sci. 2017, 106, 3179–3187. [CrossRef]
51. Kou, L.; Bhutia, Y.D.; Yao, Q.; He, Z.; Sun, J.; Ganapathy, V. Transporter-guided delivery of nanoparticles to
improve drug permeation across cellular barriers and drug exposure to selective cell types. Front. Pharmacol.
2018, 9, 1–16. [CrossRef]
52. Wang, F.; Li, L.; Liu, B.; Chen, Z.; Li, C. Hyaluronic acid decorated pluronic P85 solid lipid nanoparticles as a
potential carrier to overcome multidrug resistance in cervical and breast cancer. Biomed. Pharmacother. 2017,
86, 595–604. [CrossRef]
53. Shi, S.; Zhou, M.; Li, X.; Hu, M.; Li, C.; Li, M.; Sheng, F.; Li, Z.; Wu, G.; Luo, M.; et al. Synergistic active
targeting of dually integrin αvβ3/CD44-targeted nanoparticles to B16F10 tumors located at different sites of
mouse bodies. J. Control. Release 2016, 235, 1–13. [CrossRef]
54. Jain, A.; Kesharwani, P.; Garg, N.K.; Jain, A.; Jain, S.A.; Jain, A.K.; Nirbhavane, P.; Ghanghoria, R.; Tyagi, R.K.;
Katare, O.P. Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin. Colloids Surf.
B Biointerfaces 2015, 134, 47–58. [CrossRef]
55. Liu, J.; Meng, T.; Yuan, M.; Wen, L.; Cheng, B.; Liu, N.; Huang, X.; Hong, Y.; Yuan, H.; Hu, F. MicroRNA-200c
delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell. Int. J.
Nanomed. 2016, 11, 6713–6725. [CrossRef]
56. Wang, J.; Seebacher, N.; Shi, H.; Kan, Q.; Duan, Z. Novel strategies to prevent the development of multidrug
resistance (MDR) in cancer. Oncotarget 2017, 8, 84559–84571. [CrossRef]
57. Ma, L.; Yang, D.; Li, Z.; Zhang, X.; Pu, L. Co-delivery of paclitaxel and tanespimycin in lipid nanoparticles
enhanced anti-gastric-tumor effect in vitro and in vivo. Artif. Cells Nanomed. Biotechnol. 2018, 14, 1–8.
[CrossRef]
58. Liu, B.; Han, L.; Liu, J.; Han, S.; Chen, Z.; Jiang, L. Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted
solid lipid nanoparticles with synergistic antitumor activity against cervical cancer. Int. J. Nanomed. 2017, 12,
955–968. [CrossRef]
59. Clemente, N.; Ferrara, B.; Gigliotti, C.L.; Boggio, E.; Capucchio, M.T.; Biasibetti, E.; Schiffer, D.; Mellai, M.;
Annovazzi, L.; Cangemi, L.; et al. Solid lipid nanoparticles carrying temozolomide for melanoma treatment.
Preliminary in vitro and in vivo studies. Int. J. Mol. Sci. 2018, 19, 255. [CrossRef]
60. Dudhipala, N.; Puchchakayala, G. Capecitabine lipid nanoparticles for anti-colon cancer activity in
1,2-dimethylhydrazine-induced colon cancer: Preparation, cytotoxic, pharmacokinetic and pathological
evaluation. Drug Dev. Ind. Pharm. 2018, 44, 1572–1582. [CrossRef]
61. Qureshi, O.S.; Kin, H.S.; Zeb, A.; Choi, J.S.; Kin, H.S.; Kwon, J.E.; Kim, M.S.; Kang, J.H.; Ryou, C.; Park, J.S.;
et al. Sustained release docetaxel-incorporated lipid nanoparticles with improved pharmacokinetics for oral
and parenteral administration. J. Microencapsul. 2017, 34, 250–261. [CrossRef]
62. Oliveira, M.S.; Aryasomayajula, B.; Pattni, B.; Mussi, S.V.; Ferreira, L.A.M.; Torchilin, V.P. Solid lipid
nanoparticles co-loaded with doxorubicin and α-tocopherol succinate are effective against drug-resistant
cancer cells in monolayer and 3-D spheroid cancer cell models. Int. J. Pharm. 2016, 512, 292–300. [CrossRef]
63. Rompicharla, S.V.K.; Bhatt, H.; Shah, A.; Komanduri, N.; Vijayasarathy, D.; Ghosh, B.; Biswas, S. Formulation
optimization, characterization, and evaluation of in vitro cytotoxic potencial of curcumin loaded solid lipid
nanoparticles for improved anticancer activity. Chem. Phys. Lipids 2017, 208, 10–18. [CrossRef]
64. Guney, G.; Cecener, G.; Dikmen, G.; Egeli, U.; Tunca, B. Solid lipid nanoparticles: Reversal of tamoxifen
resistance in breast cancer. Eur. J. Pharm. Sci. 2018, 120, 73–88. [CrossRef]
65. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 2019, 69, 7–34. [CrossRef]
66. Xu, W.; Bae, E.J.; Lee, M.K. Enhanced anticancer activity and intracellular uptake of paclitaxel-containing
solid lipid nanoparticles in multidrug-resistant breast cancer cells. Int. J. Nanomed. 2018, 13, 7549–7563.
[CrossRef]
Nanomaterials 2019, 9, 474 20 of 20
67. Garg, N.K.; Singh, B.; Jain, A.; Nirbhavane, P.; Sharma, R.; Tyagi, R.K.; Kushwah, V.; Jain, S.; Katare, O.P.
Fucose decorated solid-lipid nanocarriers mediate efficient delivery of methotrexate in breast cancer
therapeutics. Colloids Surf. B Biointerfaces 2016, 146, 114–126. [CrossRef]
68. Ji, P.; Yu, T.; Liu, Y.; Jiang, J.; Xu, J.; Zhao, Y.; Hao, Y.; Qiu, Y.; Zhao, W.; Wu, C. Naringenin-loaded solid lipid
nanoparticles: Preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics. Drug Des.
Dev. Ther. 2016, 10, 911–925. [CrossRef]
69. Rosière, R.; Van Woensel, M.; Gelbcke, M.; Mathieu, V.; Hecq, J.; Mathivet, T.; Vermeersch, M.; Van
Antwerpen, P.; Amighi, K.; Wauthoz, N. New folate-grafted chitosan derivative to improve delivery of
paclitaxel-loaded solid lipid nanoparticles for lung tumor therapy by inhalation. Mol. Pharm. 2018, 15,
899–910. [CrossRef]
70. Naseri, N.; Zakeri-Milani, P.; Hamishehkar, H.; Pilehvar-Soltanahmadi, Y.; Valizadeh, H. Development,
in vitro characterization, antitumor and aerosol performance evaluation of respirable prepared by
self-nanoemulsification method. Drug Res. 2017, 67, 343–348. [CrossRef]
71. Serini, S.; Cassano, R.; Corsetto, P.A.; Rizzo, A.M.; Calviello, G.; Trombino, S. Omega-3 PUFA loaded in
resveratrol-based solid lipid nanoparticles: Physicochemical properties and antineoplastic activities in
human colorectal cancer cells in vitro. Int. J. Mol. Sci. 2018, 19, 586. [CrossRef]
72. Rajpoot, K.; Jain, S.K. Colorectal cancer-targeted delivery of oxaliplatin via folic acid-grafted solid lipid
nanoparticles: Preparation, optimization and in vitro evaluation. Artif. Cells Nanomed. Biotechnol. 2018, 46,
1236–1247. [CrossRef]
73. Grillone, A.; Riva, E.R.; Mondini, A.; Forte, C.; Calucci, L.; Innocenti, C.; de Julian Fernandez, C.; Cappello, V.;
Gemmi, M.; Moscato, S.; et al. Active targeting of sorafenib: Preparation, characterization and in vitro
testing of drug-loaded magnetic solid lipid nanoparticles. Adv. Healthc. Mater. 2015, 4, 1681–1690. [CrossRef]
74. Rodenak-Kladniew, B.; Islan, G.A.; de Bravo, M.G.; Durán, N.; Castro, G.R. Design, characterization and
in vitro evaluation of linalool-loaded solid lipid nanoparticles as potent tool in cancer therapy. Colloids Surf.
B Biointerfaces 2017, 154, 123–132. [CrossRef]
75. Rahiminejad, A.; Dinarvand, R.; Johari, B.; Nodooshan, S.J.; Rashti, A.; Rismani, E.; Mahdaviani, P.;
Saltanatpour, Z.; Rahiminejad, S.; Raigani, M.; et al. Preparation and investigation of indirubin-loaded SLN
nanoparticels and their anti-cancer effects on human glioblastoma U87MG cells. Cell Biol. Int. 2019, 43, 2–11.
[CrossRef]
76. Battaglia, L.; Muntoni, E.; Chirio, D.; Peira, E.; Annovazzi, L.; Schiffer, D.; Mellai, M.; Riganti, C.;
Salaroglio, I.C.; Lanotte, M.; et al. Solid lipid nanoparticles by coacervation loaded with a methotrexate
prodrug: Preliminary study for glioma treatment. Nanomedicine 2017, 12, 639–656. [CrossRef]
77. Neves, A.R.; Queiroz, J.F.; Lima, S.A.C.; Reis, S. Apo E-functionalization of solid lipid nanoparticles enhances
brain drug delivery: Uptake mechanism and transport pathways. Bioconjug. Chem. 2017, 28, 995–1004.
[CrossRef]
78. Bhushan, S.; Kakkar, V.; Pal, H.C.; Mondhe, D.M.; Kaur, I.P. The augmented anticancer potential of AP9-cd
loaded solid lipid nanoparticles in human leukemia Molt-4 cells and experimental tumor. Chem. Biol. Interact.
2016, 244, 84–93. [CrossRef]
79. Akanda, M.H.; Rai, R.; Slipper, I.J.; Chowdhry, B.Z.; Lamprou, D.; Getti, G.; Douroumis, D. Delivery of
retinoic acid to LNCap human prostate cancer cells using solid lipid nanoparticles. Int. J. Pharm. 2015, 493,
161–171. [CrossRef]
80. Cassano, R.; Mellace, S.; Marrelli, M.; Conforti, F.; Trombino, S. α-Tocopheryl linolenate solid lipid
nanoparticles for the encapsulation, protection and reléase of the omega-3 polyunsaturated fatty acid:
In vitro anti-melanoma activity evaluation. Colloids Surf. B Biointerfaces 2017, 151, 128–133. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
